Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05686044 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
A Phase 2 study, sponsored by Annovis Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 351
- Enrollment target
NCT05686044: Completed Phase 2 study, sponsored by Annovis Bio.
NCT05686044 is a Phase 2 study that has completed, run by Annovis Bio. The registered enrollment target is 351 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (164% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05686044, a Phase 2 study, has completed, sponsored by Annovis Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 351 participants
- Enrollment target
Study Summary
The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease. Study details include: The double-blind treatment duration will include a screening period of up to 42 days followed by 12 weeks of treatment at home. The study duration will be 4-5 months. There will be 4 in-clinic visits and 1 phone call.
Primary Outcome
Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) measures cognitive functions and non-cognitive functions such as mood and behavior. It was designed to measure the cognitive and behavioral domains known to be affected in Alzheimer disease, including memory, language, orientation, construction, and planning of simple designs, and completed simple goal-oriented behaviors. Specifically, the ADAS-Cog comprises ratings from 11 components: word recall, word recognition, constru
Interventions
- DRUG Placebo
- DRUG Buntanetap/Posiphen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2024-02-13 |
| Phase | Phase 2 |
What the finished NCT05686044 record still lists
NCT05686044 is an interventional study that assigns participants to a tested intervention. The registered 351 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (164% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05686044 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05686044 about?
NCT05686044 is a clinical study titled "A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD". The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease. Study details include: The double-blind treatment duration will include a screening period of up to 42 days f...
What is the current status of trial NCT05686044?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 351 participants. The study started on 2023-04-01. Estimated completion is 2024-02-13.
What interventions are being tested in trial NCT05686044?
The interventions under investigation include: Placebo (DRUG), Buntanetap/Posiphen (DRUG).
Who is sponsoring clinical trial NCT05686044?
This trial is sponsored by Annovis Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05686044's enrollment target sits among peer trials
351 130th of 2000 higher than 1,871 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06241456 · 351 participants · Phase 1
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- NCT06576726 · 351 participants
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
- NCT07043400 · 351 participants · Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT07261423 · 351 participants · NA
Pollution Intervention to Impact Kids Asthma Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI